Celgene Corporation

(CELG) Trade

By |

Profile

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Contact Information

Website: www.celgene.com
Email: ir@celgene.com
Main Phone: +1 908 673-9000
Address: 86 Morris Avenue
State: NJ
City / Town: Summit
Country: USA
Postal Code: 07901

Issuer Information

Exchange: NGS
CEO: Mark J. Alles
Employees: 7467
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Contact Information

Website: www.celgene.com
Email: ir@celgene.com
Main Phone: +1 908 673-9000
Address: 86 Morris Avenue
State: NJ
City / Town: Summit
Country: USA
Postal Code: 07901

Issuer Information

Exchange: NGS
CEO: Mark J. Alles
Employees: 7467
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 86.50 $ 0.50 (0.58%)
Last Price 86.50 Change $ 0.50 Change % 0.58 Tick N/A
Bid 86.30 Bid Size 100.00 Ask 86.80 Ask Size 400.00
Open 85.79 High 86.94 Low 85.79 Prev Close 86.00
Last Trade Volume 9 mi 52 Wk Hi 106.67 52 Wk Low 58.59
Market Cap 60.6 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 700,238,758.00 EPS (TTM) 3.95 PE Ratio 21.80 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 22 112
Number of Buys 12 61
Number of Sells 10 51
Net Activity 49704 125539
Last 10 Buys Shares
Mark J. Alles 1,000
Mark J. Alles 1,000
Michael W. Bonney 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Rodman L. Drake 1,000
Rodman L. Drake 1,000
James J. Loughlin 1,000
Jacqualyn A. Fouse 1,000
Rodman L. Drake 1,000
Last 10 Sell Shares
Michael D. Casey 1,000
James J. Loughlin 1,000
Gilla Kaplan 1,000
James J. Loughlin 1,000
Ernest Mario 1,000
Gilla Kaplan 1,000
Gilla Kaplan 1,000
Terrie Curran 1,000
Gilla Kaplan 1,000
Michael D. Casey 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 163 163 163 163
Low Target Price Estimate 92 92 92 92
Mean Target Price Estimate 120.55 120.55 121.05 120.55
Standard Deviation 24.61 24.61 24.18 24.61
Date of Most Recent Estimate 06/04/18 05/29/18 05/22/18 06/04/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 13 14 15 14
Moderate Buy 1 1 0 0
Hold 12 12 13 13
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.96 1.93 1.93 1.96